Clinical trials: Insomnia, Primary
Insomnia
Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)
This trial is a 52-week, open-label extension trial to investigate safety and to explore efficacy of Org 50081 (Esmirtazapine) in participants who completed Protocol 176001 (P05706) (NCT00482612) or 176002 (P05707) (NCT00506389).
- Trial name
- NCT00610675
- Testing
- Org 50081
- Volunteers
- 346 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Insomnia
A Study of Gaboxadol in Primary Insomnia
To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia.
- Trial name
- NCT00209924
- Testing
- Gaboxadol
- Where
- Sweden
- Volunteers
- 505 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)
This is a multicenter study to test the hypothesis that suvorexant (MK-4305) is superior to placebo in improving insomnia as measured by change from baseline in: subjective total sleep time and time to sleep onset, wake time…
- Trial name
- NCT01097629
- Testing
- Suvorexant High Dose (HD), Suvorexant Low Dose (LD)
- Volunteers
- 1,020 people
- Sponsor
- Merck Sharp & Dohme LLC
Tension Headaches, Stress
Temple Massager System Study in Women Ages 35-65
The goal of this observational study is to learn how the Temple Massager System affects stress, emotional wellbeing, sleep, and quality of life in women aged 35 to 65.
- Conditions
- Tension Headaches, Stress, Sleep Quality, Quality of Life
- Trial name
- NCT07639658
- Testing
- Temple Massager System
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Meisch Temple Massager, Inc.
Sleep Disorders
Sleep Satisfaction and Psychomotor Performance of Adults
Primary Objective: To assess sleep satisfaction before and after Zolpidem CR (Ambien CR) administration Secondary Objective: To assess Psychomotor Performance before and after Zolpidem CR (Ambien CR) administration
- Trial name
- MORFEO CR (NCT01097382)
- Testing
- ZOLPIDEM
- Where
- 6 sites in Argentina
- Volunteers
- 30 people
- Sponsor
- Sanofi
Primary Insomnia
A Study of Gaboxadol in Primary Insomnia
To evaluate the safety and tolerability of gaboxadol in primary insomnia.
- Trial name
- NCT00209963
- Testing
- Gaboxadol
- Volunteers
- 600 people
- Sponsor
- H. Lundbeck A/S
Insomnia
A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)
The purpose of this study is to investigate and evaluate the bioequivalence and food effect of SEP 190-102 in Japanese healthy subjects by assessing the pharmacokinetics parameters.
- Trial name
- NCT01055834
- Testing
- Eszopiclone 3 mg, Eszopiclone 1 mg
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Insomnia
An Exploratory Study of NBI-34060 Capsules and Next Day Functioning
NBI-34060 is an investigational (research) medication being studied in people with insomnia. The current study is designed to evaluate how people, who experience a nighttime awakening with difficulty returning to sleep, feel…
- Trial name
- NCT00525941
- Testing
- NBI-34060
- Where
- 4 sites in United States
- Sponsor
- Neurocrine Biosciences
Primary Insomnia
Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
- Trial name
- NCT00266357
- Testing
- MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)
- Volunteers
- 50 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
A Study of Gaboxadol in Primary Insomnia
To evaluate the safety and tolerability of gaboxadol in primary insomnia.
- Trial name
- NCT00209846
- Testing
- Gaboxadol
- Where
- Sweden
- Volunteers
- 320 people
- Sponsor
- H. Lundbeck A/S
Insomnia, Migraine
Treatment of Insomnia in Migraineurs
It is hypothesized that treating insomnia in migraineurs, many of whom also have tension headaches, prolongs total sleep time to the extent that it decreases overall headache frequency.
- Trial name
- NCT00812214
- Testing
- eszopiclone
- Volunteers
- 113 people
- Sponsor
- MedVadis Research Corporation
Insomnia
A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
This study will establish the safety and tolerability of suvorexant (MK-4305) when administered for up to 14 months. Participants will be randomized to receive suvorexant or placebo for a 12-month double-blind (DB) Treatment…
- Trial name
- NCT01021813
- Testing
- Suvorexant
- Volunteers
- 781 people
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia
Investigation of the Efficacy and Safety of CHI-921 in Insomnia.
Insomnia is a disorder where people are having trouble sleeping and can include difficulty falling asleep, staying asleep and waking up too early, as well as having unrefreshing sleep.
- Trial name
- NCT03984604
- Testing
- CHI-921
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Canopy Growth Corporation
Sleep Initiation and Maintenance Disorders
Efficacy Study of EVT 201 to Treat Insomnia
The purpose of this study is to determine whether a compound known as EVT 201 is effective in treating people diagnosed with primary insomnia ( difficulty sleeping with no other significant contributing factor, such as…
- Trial name
- NCT00380003
- Testing
- EVT 201
- Where
- 5 sites in United States
- Volunteers
- 66 people
- Sponsor
- Evotec Neurosciences GmbH
Primary Insomnia
Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs
The aim of this placebo controlled study is to investigate the effect of 2 mg melatonin Slow Release (Circadin®) on the sleep/wake cycle in elderly insomniac out-subjects, aged 55 years or more.
- Trial name
- Neu I (NCT00816673)
- Testing
- Circadin
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Sleep Initiation and Maintenance Disorders, Insomnia
Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia
This study is designed to find the optimal (best) doses of GW679769 that could be given daily to promote sleep onset and maintain sleep during the night without significant next-day thinking impairment and drowsiness in subjects…
- Trial name
- NCT00280423
- Testing
- GW679769
- Where
- 71 sites in United States, Canada
- Volunteers
- 342 people
- Sponsor
- GlaxoSmithKline
Sleep Initiation and Maintenance Disorders
Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties
The primary objective is to compare the potential for next-day residual effects of eplivanserin 5 mg/day and lormetazepam 1 mg/day by measuring the sleepiness in the morning using the patient's sleep questionnaire during 4 weeks…
- Trial name
- DREAMS (NCT00679900)
- Testing
- eplivanserin (SR46349), lormetazepam
- Where
- 8 sites in Chile, Estonia and 6 more
- Volunteers
- 283 people
- Sponsor
- Sanofi
Insomnia
A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006
Part A: The purpose of this study is to evaluate the safety and tolerability of single oral doses of E2006 administered in the morning to healthy male and female subjects.
- Trial name
- NCT01463098
- Testing
- E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg
- Where
- 2 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Sleep Initiation and Maintenance Disorders, Primary Insomnia
A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients
The purpose of this study is to investigate the efficacy and safety of zolpidem MR (modified release) compared to zolpidem IR (immediate release) in patients with primary insomnia.
- Trial name
- NCT01181232
- Testing
- Zolpidem MR, Zolpidem IR
- Where
- 2 sites in Taiwan
- Volunteers
- 132 people
- Sponsor
- Astellas Pharma Inc
Primary Insomnia
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)
This is a multicenter study to test the hypothesis that suvorexant (MK-4305) is superior to placebo in improving insomnia as measured by change from baseline in: subjective total sleep time and time to sleep onset, wake time…
- Trial name
- NCT01097616
- Testing
- Suvorexant High Dose (HD), Suvorexant Low Dose (LD)
- Volunteers
- 1,023 people
- Sponsor
- Merck Sharp & Dohme LLC